Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 236M 291M 256M 221M 414M 27.5B 421M 2.83B 1.1B 13.56B 1.09B 1.07B 47.11B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 264M 326M 286M 246M 462M 30.73B 471M 3.16B 1.22B 15.15B 1.22B 1.2B 52.64B EV / Sales 2026 *
2.78x
EV / Sales 2027 * 2.23x
Free-Float
81.02%
Yield 2026 *
-
Yield 2027 * -
1 day-0.38%
1 week-1.36%
Current month-2.45%
1 month+1.66%
3 months+2.85%
6 months+23.45%
Current year+26.19%
1 week 15.54
Extreme 15.54
16.36
1 month 14.88
Extreme 14.88
17.88
Current year 11.7
Extreme 11.7
18.84
1 year 9.38
Extreme 9.38
18.84
3 years 7.14
Extreme 7.14
18.84
5 years 5
Extreme 5
28.2
10 years 5
Extreme 5
845
Manager TitleAgeSince
Chief Executive Officer 58 2019-11-30
Director of Finance/CFO 51 2025-02-23
Chief Operating Officer 55 2022-08-31
Director TitleAgeSince
Chairman 64 2022-06-29
Director/Board Member 58 2017-04-03
Director/Board Member 47 2023-06-26
Date Insider Type Main position Quantity % Market Cap.
24-01-21Buy 30,228 0.2396%
23-07-05Buy 2,000 0.0016%
22-01-10Buy 30,000 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%-1.36%+32.94%+101.01% 292M
+4.02%+10.17%+57.46%+9.47% 298B
+4.93%+10.48%+33.21%-3.89% 69.19B
+2.09%+5.96%+38.83%+112.76% 8.44B
+0.92%+1.79%+4.38%-5.44% 8.27B
+2.31%-0.11%-4.11%+4.85% 4.4B
+4.94%+12.50%+7.58%+29.39% 3.64B
-1.38%-8.82%-30.10%+29.30% 3.5B
-0.86%+0.83%+43.25%+37.14% 2.62B
+2.36%+10.87%+13.02%-20.42% 2.07B
Average +1.90%+4.70%+19.65%+29.42% 40.03B
Weighted average by Cap. +3.97%+5.45%+49.54%+9.43%

Financials

2026 *2027 *
Net sales 94.7M 117M 103M 88.55M 166M 11.04B 169M 1.14B 440M 5.44B 439M 430M 18.91B 116M 143M 125M 108M 203M 13.47B 206M 1.39B 537M 6.64B 536M 524M 23.08B
Net income - -
Net Debt 27.7M 34.23M 30.06M 25.9M 48.58M 3.23B 49.47M 332M 129M 1.59B 129M 126M 5.53B 21.4M 26.44M 23.23M 20.01M 37.53M 2.5B 38.22M 257M 99.45M 1.23B 99.3M 97.12M 4.27B
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
26-06-25 CHF 15.90 -0.38% 36,703
26-06-24 CHF 15.96 -0.62% 44,810
26-06-23 CHF 16.06 +0.63% 59,060
26-06-22 CHF 15.96 +0.13% 23,506
26-06-19 CHF 15.94 -1.12% 36,883
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15.90CHF
Average target price
27.50CHF
Spread / Average Target
+72.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANN Stock